JPMorgan Chase & Co. Decreases Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

JPMorgan Chase & Co. lowered its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 71.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,571 shares of the company’s stock after selling 385,349 shares during the quarter. JPMorgan Chase & Co.’s holdings in Amphastar Pharmaceuticals were worth $5,702,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wellington Management Group LLP bought a new stake in Amphastar Pharmaceuticals in the 3rd quarter valued at about $957,000. Orion Portfolio Solutions LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $239,000. Barclays PLC lifted its holdings in Amphastar Pharmaceuticals by 53.3% in the 3rd quarter. Barclays PLC now owns 74,456 shares of the company’s stock valued at $3,613,000 after acquiring an additional 25,878 shares during the last quarter. Geode Capital Management LLC boosted its position in Amphastar Pharmaceuticals by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock worth $44,674,000 after acquiring an additional 14,015 shares during the period. Finally, Invst LLC boosted its stake in shares of Amphastar Pharmaceuticals by 23.6% during the 3rd quarter. Invst LLC now owns 14,390 shares of the company’s stock valued at $698,000 after buying an additional 2,752 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $23.35 on Friday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $22.64 and a twelve month high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm’s 50 day moving average price is $27.78 and its two-hundred day moving average price is $37.36. The firm has a market cap of $1.11 billion, a P/E ratio of 7.78, a PEG ratio of 2.19 and a beta of 0.79.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on AMPH shares. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, March 21st. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.